✦ LIBER ✦
Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-based model: extended follow-up of a phase II trial
✍ Scribed by Dytfeld, Dominik; Griffith, Kent A.; Friedman, Judah; Lebovic, Daniel; Harvey, Colleen; Kaminski, Mark S.; Jakubowiak, Andrzej J.
- Book ID
- 120979933
- Publisher
- Informa plc
- Year
- 2011
- Tongue
- English
- Weight
- 618 KB
- Volume
- 52
- Category
- Article
- ISSN
- 1042-8194
No coin nor oath required. For personal study only.